Press Releases | Mysite

MBF Theraupeutics™

PRESS RELEASES

MBF Therapeutics Announces the Appointment of Two New Board Members

November 19, 2020

MBF Therapeutics Collaborates with Life Science Research Leaders to Develop a Next Generation Immunotherapeutic Vaccine for SARS CoV-2

MBF Therapeutics Teams Experts to Develop Effective, Broad-Spectrum Immunotherapeutic African Swine Fever Virus Vaccine

MBF Therapeutics Teams Experts to Develop Effective, Broad-Spectrum Immunotherapeutic African Swine Fever Virus Vaccin e

January 10, 2020

MBF Therapeutics Names Ronald Cravens, MS, DVM, Executive Vice President of Business Developmen t

January 7, 202 0

MBF Therapeutics signs exclusive option agreement for UNC proprietary checkpoint inhibitors and vaccine delivery technolog y

MBF Therapeutics’ Founder and CEO Tom Tillett to speak at ASPIRE Philadelphia Dealmakers Conferenc e

SwRI, MBF Therapeutics sign exclusive license for proprietary drug delivery syste m

Wistar Expands Collaboration & Signs Exclusive License Agreement with Man’s Best Friend Therapeutics to Develop Novel Veterinary Vaccine Technolog y

November 2, 201 7

MBF Therapeutics Inc. to present at Philadelphia PACT Investor Conferenc e

October 30, 201 7

The Wistar Institute and Man’s Best Friend Therapeutics Announce Partnership to Advance Canine Melanoma Cancer Vaccin e

November 17, 20 16